This technology includes endometrial cancer cell lines for use in molecular and cellular studies to determine the effects of cancer-associated FBXW7 (F-box and WD repeat domain-containing 7) mutations, including but not limited to biochemical studies, proteomic studies, and drug sensitivity/resistance studies. Clustered Regularly Interspaced Palindromic Repeats (CRISPR) editing was used to knock-in individual FBXW7 mutations into the ARK1 serous EC cell line, which lacks detectable endogenous FBXW7 mutation(s). For each CRISPR-edited cell line, and parental ARK1 cells, STR (Short Tandem Repeat) profiles were generated. STR profiles of CRISPR-edited cell lines authenticated to the parental ARK1 line.
Development of therapeutic targeting of dysregulated gene expression, protein expression, signal transduction, metabolomics linked to FBXW7 mutations in human endometrial cancer.
The generation of ARK1 cell lines, CRISPR-edited to knock-in a FBXW7 mutation(s), provides unique reagents to use in molecular and cellular studies to determine the effects of cancer-associated FBXW7 mutations including but not limited to biochemical studies, proteomic studies, and drug sensitivity/resistance studies.